top of page

Board of Directors


Chairman of the Board – Damian Marron

​Damian Marron is an experienced Board Chair and Non-Executive Director, corporate advisor and former serial CEO with a successful track record of value creation through public and venture capital financing, portfolio planning, M&A, licensing agreements and R&D collaborations, both as an executive and in advisory roles. He has notably specialized in immuno-oncology, cell therapy and orphan diseases. Damian is currently Non-Executive Chair of the Board at Targovax ASA and Cytoseek Ltd, Non-Executive Director at Cantargia AB, Bone Therapeutics SA and Resolys Bio Inc. He is also Head of Biopharma with Treehill Partners, a global pure-play healthcare advisory firm. Damian has formerly been Chair of the Board of Directors of PepGen Ltd and the CEO at Agalimmune Ltd, TxCell SA, Cytheris SA, and Trophos SA. He is a pharmacologist and cell biologist by training and spent ten years in big pharma R&D. Mr Marron is a British and Irish citizen; he resides in France.

Richard Bungay greyscale.png

CEO - Richard Bungay

Richard was formerly Chief Executive Officer of AIM-listed Diurnal Group plc, where he led the sale of the company to Neurocrine Biosciences in October 2023. Richard has over 25 years’ experience in senior roles in the biotechnology and pharmaceutical sectors, including as CFO and COO at Mereo Biopharma and CEO of Chroma Therapeutics. Richard has been involved in fundraisings totalling over $250 million, along with the negotiation and execution of multiple business development deals. Richard also has extensive experience of taking novel drugs from research through to clinical development and commercialisation and has been involved with the development of six currently marketed drugs, including three novel biological agents. Richard qualified with Deloitte as a Chartered Accountant and has a First Class degree in Chemistry from Nottingham University. Richard is a Non-executive Director of AIM-listed Cambridge Cognition and it's spin-out Monument Therapeutics. 

Fred crop.jpg

Co-founder/CSO – Fred Garzoni

​Mr Frederic Garzoni is an inventor and entrepreneur with more than 10 years’ experience in managing R&D projects and high-tech platforms at top institutions, including  European Molecular Biology Laboratory (EMBL) Grenoble, The French Alternative Energies and Atomic Energy Commission (CEA) and Centre National de la Recherche Scientifique (CNRS). Fred has co-authored high-impact publications in top ranked journals including Nature and Science. Fred led the production platform in the multimillion Euro EC consortium project ComplexINC, flagged as 'breakthrough' by the Commission, and delivered high-value drug discovery targets for global pharma enterprises. Award-winning innovator, Fred received BBSRC Future Talent and Mobility Award 2017, SynBiCITE 4D-MBA Closest-to-Market Award and Start-Up Award. Fred moved from France to Bristol (UK) to incorporate and establish Imophoron Ltd. Fred has been appointed Franco-British Young Leader (2022 cohort) by the Franco-British Council.


 Non-executive Director - Harry Destecroix

Harry Destecroix is a supramolecular chemist and CEO of Science Creates Ventures and Incubators. Previously, he was the founder and former CEO of Ziylo Ltd, a business he successfully grew and exited, within four years of founding, in a Share Purchase Agreement to Novo Nordisk A/S, for a potential earnout of $800m. Harry founded the Science Creates incubators in Bristol’s St Philips and Old Market districts that help support the current deep tech ecosystem. In the process of establishing the incubators, he has helped multiple spin outs to emerge, advising them on strategy and helping them build the initial team. Harry sits on the University of Bristol Investment Committee.

Mike's picture.jpeg

Non-executive Director - Mike Westby, PhD. 

Mike is a senior Exec with over 20 years R&D Pharma and Biotech Industry experience, including at Roche and Pfizer. He led the Anti-Infectives Research Group at Pfizer’s Sandwich R&D site and played a key role in progressing novel compounds through clinical trials, including maraviroc (Selzentry) a first-in-class HIV entry inhibitor. Mike’s team also supported Pfizer’s preclinical vaccine programs, comprising DNA-based vaccines for RSV and HSV.  As founder and CEO of three start-up Biotechs, Mike has successfully raised >£40m in dilutive and non-dilutive funds. Mike is currently CSO of Centauri Therapeutics Limited, a privately-owned UK Biotech with a novel immunotherapeutic platform (“Alphamers”) for infectious diseases. Mike also holds NED positions on the Boards of a number of early stage Biotechs. Mike was the co-founder of Agalimmune Ltd, a preclinical stage biotech that developed a novel immunotherapeutic (AGI-134) for treating solid tumours. Agalimmune was successfully sold to BiolineRx in 2017 and AGI-134 is now in early clinical development. Mike trained in Molecular Biology and Biochemistry at the University of Durham, obtained his PhD at Warwick University and studied immunology and microbiology as a post-doctoral research fellow at St George’s Hospital Medical School, London. He is the co-author of more than 50 manuscripts and patents. 

bottom of page